Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 4 of 15

 
 

Smith & Nephew (NYSE:SNN)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
4 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
N/A

About Smith & Nephew

Smith & Nephew logoSmith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/24/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy
6/5/2024UBS GroupUpgradeNeutral ➝ Buy
11/28/2023BarclaysUpgradeUnderweight ➝ Equal Weight
11/3/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
10/31/2023HSBCUpgradeHold ➝ Buy
10/13/2023Stifel NicolausInitiated CoverageHold
8/8/2023UBS GroupUpgradeSell ➝ Neutral
4/27/2023HSBCDowngradeBuy ➝ Hold
4/11/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
3/29/2023BarclaysDowngradeOverweight ➝ Underweight
 

[SHOCKING] Crypto Document Leak… (Ad)

Imagine if you could go back to 2009 and buy Bitcoin at $0.01. Or jump to 2015 and grab Ethereum at $0.75. We've created the next best thing: It's called "Crypto Revolution," and it's not just a book… it's your potential ticket to financial time travel.

Download your digital copy of "Crypto Revolution" now (limited-time offer).